Not conducted by MedTech Research Group
issued a position statement to address barriers to IBD care
doi: 10.3389/fnut.2024.1307734
The mechanism is likely related to slowed bile flow from reduced gallbladder contraction, compounded by rapid weight loss (which concentrates bile and promotes stone formation)
Available aggregate data suggest that glucagon-like peptide-1 (GLP-1) receptor agonists (exenatide, liraglutide, lixisenatide, dulaglutide, or semaglutide) are not associated with AF onset, with the only possible exception of albiglutide [98, 99]
Semaglutide is the active ingredient in Wegovy, Ozempic, and Rybelsus